Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill is the first oral drug to mimic the GLP-1 hormone.
It is priced significantly lower than injectable weight-loss treatments.
Self-paying patients can access the starting dose for $149 per month.
Higher doses will range from $199 to $299 monthly after April.
Patients with insurance may pay as little as $25 per month.
The pill offers a needle-free alternative, potentially expanding patient demand.
US injectable GLP-1 drugs typically cost around $1,000 per month.
Novo hopes the launch will help regain market share lost to rivals.
Competition has intensified with injectable drugs from Eli Lilly.
The Wegovy pill is currently approved only in the US.
UK regulators are reviewing approval and are expected to decide later this year.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
Golden Gate Times delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:
© 2026 Golden Gate Times. All Rights Reserved.